Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03856411
Recruitment Status : Recruiting
First Posted : February 27, 2019
Last Update Posted : October 28, 2019
Sponsor:
Information provided by (Responsible Party):
Shanghai Junshi Bioscience Co., Ltd.

Tracking Information
First Submitted Date  ICMJE January 24, 2019
First Posted Date  ICMJE February 27, 2019
Last Update Posted Date October 28, 2019
Actual Study Start Date  ICMJE March 18, 2019
Estimated Primary Completion Date April 14, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 25, 2019)
PFS [ Time Frame: Up to 2 approximately years ]
Progression free survival (PFS) evaluated by investigators according to the response evaluation criteria in solid tumors (RECIST 1.1)
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 25, 2019)
  • OS [ Time Frame: Up to 2 approximately years ]
    Overall survival (OS)
  • PFS [ Time Frame: Up to 2 approximately years ]
    PFS evaluated by the Blinded Individual Review Committee (BIRC) based on RECIST1.1 criteria
  • ORR [ Time Frame: Up to 2 approximately years ]
    Objective response rate (ORR) evaluated by investigators and BIRC based on RECIST1.1
  • DOR [ Time Frame: Up to 2 approximately years ]
    Duration of response (DOR) evaluated by investigators and BIRC based on RECIST1.1
  • DCR [ Time Frame: Up to 2 approximately years ]
    Disease control rate (DCR) evaluated by investigators and BIRC based on RECIST1.1
  • TTR [ Time Frame: Up to 2 approximately years ]
    Time to response (TTR) evaluated by investigators and BIRC based on RECIST1.1
  • Incidence of AEs/SAEs [ Time Frame: From date of consent informed until 60 days after the last investigational product administration. Up to 2 approximately years ]
    Overall incidence of adverse events (AEs); incidence of grade 3 and above AEs; incidence of serious adverse events (SAEs); incidence of AEs leading to termination of the investigational drug; incidence of AEs interruption of the investigational drug
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC
Official Title  ICMJE A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection (JS001) or Placebo Combined With First-line Standard Chemotherapy in Treatment-naive Advanced Non-small Cell Lung Cancer (NSCLC)
Brief Summary

This is one randomized, double-blind, placebo-controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of Toripalimab injection (JS001) or placebo combined with standard 1st-line chemotherapy in treatment-naïve advanced non-small cell lung cancer (NSCLC); and evaluate the population with the best predictive biomarkers, i.e., positive diagnosis population.

About 450 subjects with advanced non-small cell lung cancer without activated EGFR mutation (exon 19 deletion, or exon 21 L858R, exon 21 L861Q, exon 18 G719X or exon 20 S768I mutations) and ALK fusion will be 2:1 randomized into two groups, JS001 combined with the standard 1st-line chemotherapy will be given in the study group whereas placebo combined with standard 1st-line chemotherapy will be given in the control group. The stratification will be based on the following factors:

PD-L1 expression (TC≥1% vs TC<1%); Smoking state (often smoking vs no smoking or infrequent smoking); Pathological type (squamous cell carcinoma vs non-squamous cell carcinoma).

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Treatment-naive Advanced Non-small Cell Lung Cancer
Intervention  ICMJE Drug: TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
TORIPALIMAB INJECTION(JS001 ) or Placebo ,240mg/6ml/vial, Q3W,up to 2 years of treatment.
Other Name: JS001, TAB001
Study Arms  ICMJE
  • Experimental: Group TORIPALIMAB combined with standard chemotherapy
    Intervention: Drug: TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
  • Placebo Comparator: Group Placebo combined with standard chemotherapy
    Intervention: Drug: TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 25, 2019)
450
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 21, 2021
Estimated Primary Completion Date April 14, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Only the patients meeting all the following criteria can be eligible to participate in the trial:

  1. Histologically and/or cytologically confirmed stage IV non-small cell lung cancer and ALK fusion
  2. At least one measurable lesion 3 No history of any systemic anti-tumor therapy.

4. Agreement on providing formalin fixed tumor tissue specimen or fresh biopsy tissue from tumor lesions after diagnosis of metastasis 6. Age of 18-75 years 7. ECOG Scores 0-1; 8. Expected survival ≥ 3 months;

Exclusion Criteria:

  1. Known allergy to recombinant humanized anti-PD-1 monoclonal antibody drug and its components;
  2. Histologically or cytopathologically confirmed combination with small cell lung cancer component or sarcomatoid lesion;
  3. Current participation in and receiving other study treatment, or participation in treatment of one study drug within 4 weeks prior to administration of JS001;
  4. Previous use of systematic chemotherapy for advanced NSCLC; targeted therapy for advanced NSCLC
  5. Previous use of anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody or anti-CTLA-4 antibody (or any other antibody acting on T cells synergetic stimulation or checkpoint pathway, such as IDO, IL-2R, GITR);
  6. Chest (lung) radiotherapy > 30 Gy within 6 months prior to the start of study treatment.
  7. Active tuberculosis (TB), receiving anti-tuberculosis therapy currently or within one year prior to screening;
  8. Known active central nervous system (CNS) metastasis and/or cancerous meningitis;
  9. Spinal cord compression for which operation and/or radical radiotherapy has not been given, or no clinical evidence of stable disease for ≥4 weeks prior to enrollment after treatment for previously diagnosed spinal cord compression
  10. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage
  11. Uncontrollable or symptomatic hypercalcemia
  12. Clinically uncontrolled active infection, including but not limited to acute pneumonia;
  13. Uncontrollable major epileptic seizure or superior vena cava syndrome
  14. Previous or current combination with other malignancies ;
  15. History of idiopathic pulmonary fibrosis, organized pneumonia (e.g., obliterating bronchiolitis), drug induced pneumonia, idiopathic pneumonia or evidence of active pneumonia during chest CT scanning for screening;
  16. Known hepatic diseases of clinical significance, including active viral hepatitis, alcoholic hepatitis or other hepatitis, liver cirrhosis, fatty liver, hereditary liver disease;
  17. Use of systemic immunosuppressive therapy for any active autoimmune disease within two years prior to Day 1 of the 1st cycle;
  18. Vaccination of live-virus vaccine within 30 days after the start of planned treatment
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Jie Wang, Prof +8610-87788495 zlhuxi@163.com
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03856411
Other Study ID Numbers  ICMJE JS001-019-III-NSCLC
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Shanghai Junshi Bioscience Co., Ltd.
Study Sponsor  ICMJE Shanghai Junshi Bioscience Co., Ltd.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Shanghai Junshi Bioscience Co., Ltd.
Verification Date March 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP